Choosing Among BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.

The faculty emphasize that, despite differences in administration schedules, formulations, toxicity profiles, and clinical trial designs, currently available BCMA-directed bispecific antibodies have demonstrated meaningful clinical activity across heavily pretreated patient populations.

Dr. Huff highlights the importance of institutional experience, formulary availability, and familiarity with toxicity management when incorporating these therapies into practice.

Dr. Mewawalla discusses how access to multiple agents allows for individualized treatment discussions and shared decision-making, while noting that patient preferences and logistical considerations often influence final treatment choices.

The panel also reflects on the challenges of cross-trial comparisons and the need for continued clinical experience and longer follow-up data to better understand potential differences among BCMA-targeted therapies in RRMM.